OUR PURPOSE PIONEERING SCIENCE COMMUNITY REPORTING 88 BIOGEN 2021 YEAR IN REVIEW PATIENTS OUR PEOPLE ENVIRONMENT Promoting environmental sustainability While climate is an urgent priority, Biogen also continues to advance our commitments to a range of other environmental concerns, including water and waste. Biogen actively participates in industry groups to collaborate on environmental issues of shared concern. Examples include the Pharmaceutical Product Stewardship Working Group (PPSWG) in the U.S., the EHS Expert Group that advises the European Federation of Pharmaceutical Industries and Associations (EFPIA) in Europe, the Pharmaceutical Supply Chain Initiative (PSCI), the Climate Group and Ceres, among others. In addition, we work to monitor and respond to emerging legislation and stakeholder input on environmental issues. Advancing Sustainable Drug Development In 2021, Biogen developed new Principles of Sustainable Drug Development to promote sustainability, process safety and efficiency in the ways Biogen discovers, develops and manufactures potentially life-changing therapies. This effort brings both longstanding and new initiatives together under a common framework that involves: – Designing processes that protect workers, patients, and the environment. – Minimizing the use of potentially toxic, hazardous, biological, and environmentally harmful substances. – Minimizing the use of energy and other resources in critical processes in the early stages of development. – Purchasing renewable energy as part of Biogen’s long-term commitment to go beyond net zero to fossil fuel free. – Avoiding waste, including reducing, refining, replacing, renewing and recycling any commodity that cannot be eliminated. – Working toward continuous improvement. Last year, Biogen also created a Sustainability Team, which is working to incorporate the Principles into company-wide ways of working. Specifically, Biogen plans to: – Establish a baseline and assess the current state of processes around sustainability, as well as any limiting factors. – Set goals and metrics to measure progress on sustainable product development. – Review progress and goals periodically. For example, we now are using flow chemistry to increase energy efficiency with some of our large reactors. With this approach, instead of cooling an entire reactor to –78°C, which is required for some investigational medicines, we only have to cool down part of a flow chemistry process where the relevant reaction is happening. To limit our use of elements that are in limited supply, we are applying enzymes to initiate some chemical reactions or switching to earth abundant metal catalysts. We not only avoid the cost of a rare element but also ensure our processes are sustainable for future generations. As part of our Sustainable Product Development efforts, Biogen also has committed to champion best practices in sustainability with a range of stakeholders, including our global workforce, suppliers, vendors, contractors and the external community. Biogen participates in a number of collaborations, including with the American Chemical Society’s Green Chemistry Institute (ACS GCI) Pharmaceutical Roundtable and the IQ Consortium’s Green Chemistry Working Group. They allow us to collaborate in the pre-competitive space with leaders in the field from both academia and industry and take advantage of online tools to develop greener processes.